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medication dose should be monitored closely. We need 
studies that document the maternal well-being and fetal 
safety of maternal tapering of the OMT-medication during 
pregnancy.  © 2015 S. Karger AG, Basel 
 Introduction 
 Opioid maintenance treatment (OMT) with either 
methadone or buprenorphine has become the treatment 
of choice for opioid-dependent pregnant women  [1, 2] . 
Forty to 90% of neonates exposed to methadone or bu-
prenorphine in utero, will develop a neonatal abstinence 
syndrome (NAS) after delivery  [3, 4] . NAS is character-
ized by a multitude of symptoms which, although easy to 
identify in at-risk babies, may prove to be a challenge to 
treat and generally results in prolonged hospital stay. 
There seems to be general agreement that maternal with-
drawal will also lead to fetal withdrawal, but the with-
drawal in utero is difficult to monitor. The professionals 
cannot observe the fetal withdrawal in the same way as 
they observe the NAS of the neonate  [5, 6] .
 Even though international and national treatment 
guidelines do not recommend pregnant women to taper 
their OMT-medication dose  [7–9] , some health profes-
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 Abstract 
 Background: The tapering of methadone or buprenorphine 
during pregnancy is an understudied and controversial is-
sue. The aim of this study was to determine to what extent 
women tapered their opioid medication dose during preg-
nancy and what the neonatal outcomes were for those who 
tapered compared to the women who did not.  Methods: 
The  study was a mixed prospective/retrospective national 
cohort study of 123 Norwegian women in opioid mainte-
nance treatment (OMT) during pregnancy and their neo-
nates. A standardized questionnaire was administered to 
the women and medical information that could be used for 
verification was collected from hospitals and municipalities. 
 Results: Two of the women came off the OMT-medication 
during pregnancy and another 15% tapered their OMT-med-
ication dose more than 50%. The birth weights of metha-
done-exposed neonates of the women who tapered more 
than 50% were significantly higher than for the methadone-
exposed neonates of the women tapering between 11 
and 50%. No other significant differences were found.  Con-
clusion: Pregnant women in OMT who taper their OMT-
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sionals advise their patients to lower their OMT-medica-
tion dose during pregnancy, arguing that reducing the 
dose will lower the incidence and severity of NAS  [10–
12] . Many pregnant women in OMT also want to lower 
their dose of methadone or buprenorphine, believing that 
this choice will be best for the development of their fetus. 
The scientific basis for this is debated, however.
 The main reason for recommending women not to ta-
per their OMT-medication dose during pregnancy is the 
increased risk of relapse to the use of illegal, short-acting 
opioids and other substances, which is more harmful 
both for the woman and for the fetus  [13, 14] . Opioids 
have not been recognized to have teratogenic effects, al-
though research indicates increasing concerns about vi-
suocortical function  [15–17] .
 Although a number of studies have focused on the re-
lationship between the dose of methadone or buprenor-
phine at delivery and the incidence and duration of NAS 
for the neonate, the results have not been conclusive  [18–
21] . Cleary’s meta-analysis concludes that the severity of 
NAS does not seem to depend on high versus low dose of 
methadone toward the end of pregnancy  [22] . This has 
been further confirmed in a recent study by Cleary et al. 
 [23] describing methadone dosing in a prospective cohort 
of pregnant women maintained on methadone. The inci-
dence of NAS requiring pharmacotherapy did not differ 
significantly between women who decreased their dose of 
methadone (40%) and those women who increased their 
dose of methadone (35%) during pregnancy in this cohort.
 Tapering opioid agonist medication before week 12 of 
pregnancy may increase the chance of spontaneous abor-
tion, and tapering the dose after week 32 may lead to pre-
mature labor and birth  [13] . Moreover, early case reports 
on opioid dependency in pregnancy documented cases of 
stillbirth and perinatal deaths after medical withdrawal 
 [24, 25] .
 However, the literature on methadone-assisted with-
drawal during pregnancy is sparse and inconclusive. Pub-
lished studies have mainly reported findings from rela-
tively short in-patient periods of withdrawal/tapering 
for heroin-dependent pregnant women  [11, 12, 14, 26] . 
Gradual tapers over a longer period of time for pregnant 
women stabilized on methadone or buprenorphine is the 
preferred method described in the United States and 
 Norwegian treatment guidelines  [8, 27] , if a woman chose 
to taper during pregnancy  [28] .
 Research in Norway provides a unique opportunity to 
examine tapering from opioid agonist medication be-
cause many pregnant women in OMT have attempted ta-
pering. Moreover, there is little use of illegal and legal 
drugs in this population that might confound the inter-
pretation of findings related to tapering  [29] . To our 
knowledge, this study will be the first to focus on tapering 
the methadone or buprenorphine dose for a group of 
pregnant women.
 The overall aim of the study was to describe the taper-
ing of opioid agonist medication in a cohort of pregnant 
women in Norway and the relationship between tapering 
and neonatal birth parameters and NAS. The specific 
study questions were:
 (1) To what extent did the women taper their dose of 
methadone or buprenorphine during pregnancy?
 (2) What were the characteristics of the women who 
tapered their OMT-medication dose compared to those 
women who did not? 
 (3) What were the birth and NAS parameters for the 
neonates of women, who tapered their dose of opioid ag-
onist medication versus those women who did not taper 
their dose of methadone or buprenorphine during preg-
nancy?
 Materials and Methods 
 In this study, tapering is used as the common term for all reduc-
tions in the OMT-medication dose during pregnancy for the wom-
en in our study. We do not have information about the OMT-
medication dose-tapering schedule for each individual woman. In 
the standardized questionnaire, however, the Norwegian term for 
tapering was used ( table 1 ).
 The study included a national cohort of women in Norway 
maintained on either methadone or buprenorphine who gave birth 
from 1996 to 2009 and their neonates.
 Throughout the course of the study, the national Norwegian 
OMT program had strict inclusion criteria and a high level of con-
trol, including regular urine screening for illicit/licit substance use 
 [29] . Inclusion criteria for receiving OMT were minimum 25 years 
of age, five or more years of opioid dependency and prior attempts 
at abstinence-oriented treatment. Buprenorphine was introduced in 
Norwegian OMT programs in 2000 and has been the first line drug 
since 2005. Methadone and buprenorphine have been prescribed us-
ing the same national criteria for the treatment of opioid depen-
dence, and are delivered by the same set of health professionals.
 Patients received coordinated care by individualized multidis-
ciplinary teams, including pregnancy follow-up, psychosocial care, 
continuous OMT and other specialized care needed for their sub-
stance use disorders. The lowest efficient dose of the OMT-medi-
cation was recommended throughout pregnancy with split dosing 
and/or increase in dose toward the end of pregnancy, if necessary 
 [30] .
 Participants 
 Participants were recruited through the regional centers for 
OMT and through OMT service users’ organizations. Based on 
data from the Norwegian Medical Birth Registry and the  Norwegian 
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Centre for Addiction Research, approximately 215 women in 
OMT had their first child between 1996 and 2009. We managed to 
recruit a total of 139 women who gave birth to 161 children in our 
study  [29] .
 Only one child per participant was included in our analyses, 
to avoid dependency in the data by inclusion of siblings. Further-
more, we included only those women with at least two docu-
mented opioid medication dose levels in pregnancy. Sixteen 
women had fewer dose levels and were excluded. Thus, the final 
sample included a total of 123 women and their newborns: 
80 (65%) women in methadone maintenance treatment (MMT) 
and 43 (35%) in buprenorphine maintenance treatment (BMT) 
in pregnancy. These women constituted 57% of the total popula-
tion of pregnant women in OMT during the study period. How-
ever, we reached 75% of the target population, but for reasons 
mentioned above, we only included 123 women/neonates in this 
study.
 Among women in our cohort who had more than one preg-
nancy, we chose their first pregnancy, while they were in OMT.
 Data were collected during three different time periods  [29] . 
The first cohort was a retrospective study which took place from 
1996 to 2003 (n = 35). The second cohort was a prospective study 
from January 2005 to February 2007 (n = 33)  [31] . The third cohort 
was a retrospective study, including the years 2004 and from 
 February 2007 to March 2009 (n = 55).
 Figure 1 a and b show the relationship between the OMT-med-
ication dose at determination of pregnancy and the percentage 
change in the OMT-medication dose from the determination of 
pregnancy until delivery, for all the women using methadone and 
buprenorphine, respectively. The women in the three cohorts were 
divided into three groups, irrespective of their cohort membership, 
depending on the degree of tapering from the determination of 
pregnancy until delivery: Group 1 tapered their OMT-medication 
dose more than 50%, Group 2 tapered their OMT-medication dose 
between 11 and 50% and Group 3 had unchanged dose (±10%) or 
increased their OMT-medication dose during pregnancy ( table 2 ). 
We divided the tapering group into two since it was the effect of 
tapering that we wanted to study specifically.
Table 1.  The questions about tapering of the methadone or buprenorphine medication dose for the pregnant women in opioid mainte-
nance treatment (OMT)
1 What was the dose of methadone/buprenorphine when you realized that you were pregnant?
2 Did you attempt to taper the dose of OMT-medication during pregnancy? (no/yes)
3 In which pregnancy week was the tapering started?
4 What was the lowest dose of your OMT-medication during pregnancy?
5 In which pregnancy week did you stop the tapering?
6 What was the dose of methadone/buprenorphine at delivery?
 The information concerning changes of the OMT-medication dose was also confirmed by health professionals.
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 Fig. 1. The figures show the relationship between the OMT-med-
ication dosages at the determination of pregnancy and the percent-
age change in OMT-medication dose from the determination of 
pregnancy until delivery.  a Methadone.  b Buprenorphine. The 
vertical lines are drawn to show the cut-off for the different taper-
ing groups: Group 1: below –50%. Group 2: between –50 and 
–10%. Group 3: above –10%. 
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 Variables and Procedures 
 A standardized questionnaire was developed, based on the 
variables used in the international literature on methadone-ex-
posed pregnancies  [32] . The questionnaire explored demographic 
characteristics of women in OMT and their opioid agonist treat-
ment, including the study questions shown in  table 1 . The birth 
parameters, the neonatal outcomes and NAS scoring and treat-
ment were also obtained by the questionnaire. Licit and illicit ex-
posures to all medications, nicotine, alcohol and illicit substances 
during the current pregnancy were reported. Self-reports of licit 
and illicit substances were utilized because our earlier study 
showed that self-reporting documented some more substance use 
than the urine testing did  [29] .
 In the first cohort, health care professionals filled in the ques-
tionnaire and thus ensured the quality of the data. The second co-
hort participated in a prospective study and data were collected in 
personal interviews in the last trimester and by telephone inter-
views three months after birth. Participants in the third cohort 
were interviewed on telephone after their child was born (median 
of 332 days), as part of a retrospective study. In the second and 
third cohorts, medical information, including the dose levels of 
opioid agonist medication and results of urine screening were con-
firmed by records from health professionals for 83% of the women. 
Similarly, hospital records concerning delivery, neonatal outcome, 
and NAS were collected for 93% of the participants in the second 
and third cohort. The collection of medical records from health 
professionals and hospitals secured the quality of the data for the 
second and third cohorts.
 Ethics 
 The study was approved by the Regional Committee for Medi-
cal and Health Care Research Ethics (REC-number: S-07238b) and 
the Norwegian Data Inspectorate. The questionnaires from the 
first cohort were sent anonymously by the health professionals to 
the center for OMT in Oslo. In the two other cohorts, all the wom-
en gave written informed consent to take part in the study.
 Statistical Analysis Strategy 
 Continuous variables were compared using independent-
samples t-tests. Discrete variables were compared using χ 2 tests. 
A significance level of 5% was chosen for all tests of significance. 
First, we conducted ‘omnibus tests’ that included all three 
groups of tapering/not tapering: one way ANOVA tests or χ 2 
tests, for continuous or discrete variables, respectively. Bivariate 
comparisons were conducted only if the ‘omnibus tests’ were 
significant. Data analyses were carried out using SPSS 22 for 
Windows.
 Results 
 Extent of Tapering 
 Two women (2%), both on methadone, but none on 
buprenorphine, managed to completely taper their OMT-
medication during pregnancy (Group 1) ( table  2 ). 
 Nineteen women (15%) tapered their opioid agonist 
medication more than 50% by the time of delivery com-
pared to their dose at determination of pregnancy (Group 
1). Thirty women (24%) tapered their OMT-medication 
dose between 11 and 50% (Group 2). Forty-two women 
(34%) had unchanged dose until delivery, defined as 
±10% of the dose used at determination of pregnancy, 
while 30 women (24%) increased their dose more than 
10% during pregnancy (Group 3). There were no signifi-
cant differences between women maintained on metha-
done compared to women maintained on buprenorphine 
with respect to the degree of tapering of their opioid ago-
nist medication.
Table 2.  Comparing the opioid maintenance treatment (OMT)-medication dose when pregnancy was determined to the medication 
dose at delivery, both for the women who initiated tapering (n = 75) and for the women who did not taper (n = 48). The tapering/not 
tapering is defined as the difference in dose of OMT-medication at determination of pregnancy compared to the dose at delivery. Wom-
en using either methadone or buprenorphine during pregnancy in Norway (1996–2009) (n = 123)
Methadone, n (%) Buprenorphine, n (%) All, n (%) Group
Tried to taper (n = 75)
Off OMT-medication at delivery 2 (3) 0 2 (2) Group 1
Tapered >50% 12 (15) 7 (16) 19 (15) Group 1
Tapered 11–50% 18 (23) 12 (28) 30 (24) Group 2
Unchanged dose ±10% 9 (11) 2 (5) 11 (9) Group 3
Increased >10% 10 (13) 3 (7) 13 (11) Group 3
Did not try to taper (n = 48)
Unchanged dose ±10% 18 (23) 13 (30) 31 (25) Group 3
Increased >10% 11 (14) 6 (14) 17 (14) Group 3
Total numbers 80 (100) 43 (100) 123 (100)
 Only one child of each woman in OMT during the period 1996–2009 was included. The first pregnancy was chosen when >1 deliv-
ery/woman.
D
ow
nl
oa
de
d 
by
: 
13
7.
10
8.
70
.6
 - 
4/
21
/2
01
6 
9:
29
:1
6 
PM
 Methadone Buprenorphine Pregnancy 
Tapering Norway 
Eur Addict Res 2015;21:253–261
DOI: 10.1159/000381670
257
 Table 3 shows the OMT-medication dose levels for the 
three groups at different stages during pregnancy. Group 
1 spent 22.8 ± 7.9 weeks on tapering, while Group 2 spent 
8.5 ± 6.2 weeks on tapering (p < 0.001).
 Maternal Characteristics 
 We compared the characteristics of all the three groups 
of tapering/not tapering women to each other ( table 4 ). 
The women in Group 2 had significantly longer educa-
tion compared with women in Group 3. No other signif-
icant differences were found in background characteris-
tics between the groups.
 The women in Group 1 were significantly more sel-
dom smokers the last month before delivery, compared 
with women in Group 3. Concerning the use of drugs, the 
women in Group 1 did not use any opioids other than 
their OMT-medication or any benzodiazepines the last 
month before delivery.
 Neonatal Outcomes 
 Bivariate analyses showed significant differences in 
birth weights of the neonates of women maintained on 
methadone in Group 1 compared to Group 2 ( table 5 ). No 
other significant differences were found concerning neo-
natal growth parameters or incidence or length of pharma-
cological treatment of NAS between the different groups 
of women in the cohort. No unfavorable pregnancy out-
comes, like preterm birth or reduced growth parameters, 
were found for the neonates of the tapering women.
 Discussion 
 The first finding in our study was that approximately 
one fifth of the women tapered their dose of methadone 
or buprenorphine by more than 50% during pregnancy. 
The second finding was that the neonatal outcomes for 
the two tapering groups were, with one exception, not 
significantly different from the neonatal outcomes of the 
women who stayed on the same dose or increased their 
OMT-medication dose during pregnancy. The difference 
found was: increased birth weights of methadone-ex-
posed neonates of the women who tapered more than 
50% compared to the methadone-exposed neonates of 
women tapering 11–50%. Notably, we did not find any 
unfavorable pregnancy outcomes for the neonates of the 
tapering mothers.
 Only 2 of the women tapered their OMT-medication 
dose completely, while another 39% of the women re-
duced their dose by more than 10% from the time preg-
nancy was determined until delivery. This means that 
41% of all the women tapered their dose by more than 
10% during their pregnancy, a finding on level with the 
results in Cleary’s study  [23] . Most of the tapering in our 
cohort was done in mid-pregnancy, during a period of 
8 to 23 weeks. The last half of the pregnancy is a period of 
rapid growth of the fetus with corresponding increase in 
the distribution volume of the OMT-medication. This 
means that women who stay on the same dose of medica-
tion will likely have a reduced blood plasma concentra-
Table 3.  The opioid maintenance treatment (OMT)-medication dose levels at different stages of pregnancy for women in Norway 1996–
2009. A comparison between women who tapered their OMT-medication dose from determination of pregnancy until delivery and 
those who had stable or increased OMT-medication dose during pregnancy (n = 123)
Group 1 (n = 21)
Tapered OMT-medication
dose >50% 
Group 2 (n = 30)
Tapered OMT-medication
dose 11–50% 
Group 3 (n = 72)
Stable or increased dose 
of OMT-medication 
OMT-medication, %
Methadone 67 60 67
Buprenorphine 33 40 33
Dose at pregnancy determination, mg, mean ± SD
Methadone 90±23 124±35 97±30
Buprenorphine 14.6±7.4 17.8±4.3 15.6±5.7
Lowest dose during pregnancy, mg, mean ± SD
Methadone 18±17 81±35 53±27
Buprenorphine 1.7±1.2 11.4±4.0 12.8±5.4
Dose at delivery, mg, mean ± SD
Methadone 20±17 93±30 107±46
Buprenorphine 2.3±0.8 12.3±3.1 17.8±6.1
Length of tapering, weeks, mean ± SD 22.8±7.9 8.5±6.2
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tion of their OMT-medication as the pregnancy develops, 
due to the increased distribution volume.
 Studies of non-pregnant adults in OMT likewise find 
correspondingly low percentages for complete tapering 
 [33–35] . However, pregnancy is probably a period where 
many women are highly motivated to taper their OMT-
medication dose, especially if they think this option is best 
for their unborn babies. At the same time, tapering is 
probably more difficult in pregnancy, due to the increased 
fluid volume and other pregnancy changes in the body. 
We also know that there is a potential risk of increased 
mortality after the termination of OMT in adults  [36–38] .
 Notably, the women who tapered the most (Group 1) 
were also the women who used least legal and illegal drugs 
the last month of pregnancy and also the women who 
smoked significantly more seldom than women who did 
not taper. There was no tendency for Group 1 to relapse 
to opioid use after the substantial taper they had accom-
plished.
 Our results show that the women, who tapered their 
OMT-medication the most, more often stopped smoking 
than the women who did not taper. A decrease of 33% in 
the smoking rate of Group 1 is substantial and may have 
impacted the neonatal outcome, even though the sub-
samples were too small to detect a significant effect.
 Tapering the OMT-medication during pregnancy 
might lead to increased prenatal stress for the woman and 
the fetus  [28] . Prenatal maternal stress has been shown to 
be associated not only with spontaneous abortion, pre-
term birth and growth-retardation for the fetus but also 
with long-term behavioral consequences, such as disor-
ders in attention and learning difficulties in the offspring 
 [39, 40] . Effects of maternal exposure to social stress dur-
ing pregnancy may lead to a variety of disadvantageous 
Table 4.  The characteristics of the pregnant women, their opioid maintenance treatment (OMT), use of cigarettes and drugs during 
pregnancy in Norway 1996–2009. A comparison between women who tapered down their OMT-medication dose and those who had 
stable or increased medication dose during pregnancy (n = 123)
Group 1 (n = 21)
Tapered OMT-
medication >50%
Group 2 (n = 30)
Tapered OMT-
medication 11–50%
Group 3 (n = 72)
Stable or increased dose
of OMT-medication
Background characteristics
Age, years, mean ± SD 29.8±4.4 31.8±4.4 32.2±5.2
Education, years, mean ± SD 10.9±1.9 12.0±1.9* 10.7±1.8
Opioid dependency prior to OMT, years, mean ± SD¤ 6.4±2.3 7.8±2.9 9.0±4.6
Parity, mean ± SD 1.4±0.6 1.9±1.0 1.9±1.1
Current pregnancy planned, % 20 24 21
Current pregnancy confirmed in pregnancy week, mean ± SD 7.7±3.9 8.3±4.8 9.4±6.0
OMT treatment
OMT started in current pregnancy, % 5 0 10
In OMT prior to pregnancy, months, mean ± SD 30.4±18.3 21.0±19.2 24.7±23.8
In-patient treatment >20 days during pregnancy, % 52 37 35
Number of days, mean ± SD 181±80 134±89 131±86
Use of cigarettes and drugs
Smoking 1 month prior to pregnancy
Percentage smoking 100 97 96
Numbers of cigarettes, mean ± SD 15.6±7.2 14.7±5.1 17.5±9.3
Smoking 1 month prior to delivery
Percentage smoking 67** 83 92
Number of cigarettes, mean ± SD 7.0±9.3 7.6±5.6 9.0±6.1
Use of other opiates, last month before delivery, % 0 0 9
Use of benzodiazepines last month before delivery, % 0 10 9
Use of other opiates, benzodiazepines, amphetamines
and/or cannabis (self-report and/or screening)
Last month before pregnancy was confirmed, % 43 41 42
Last month before delivery, % 10 17 15
 ¤ Information from after 2004 only (n = 88).
* p value <0.01 between Group 2 and Group 3, ** p value <0.01 between Group 1 and Group 3. 
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fetal and maternal outcomes  [41] . These possible conse-
quences of tapering the OMT-medication dose during 
pregnancy are seldom mentioned when discussing taper-
ing in pregnancy.
 Our results seem to support the main recommenda-
tion given by the World Health Organization and coun-
tries having evidence-based guidelines on opioid depen-
dency in pregnancy: most pregnant women with opioid 
dependency should remain in opioid agonist pharmaco-
therapy with methadone or buprenorphine  [1, 27] .
 It is important that addiction medicine experts are in-
cluded in the comprehensive, multi-professional treat-
ment approach of pregnant women in OMT. Every treat-
ment decision should be based on a sound risk-benefit 
assessment; especially, every tapering decision should be 
discussed with and supervised by the treating physician.
 The present study has a number of limitations. We 
might not have sufficient power to detect significant dif-
ferences in our relatively small groups. On the other hand, 
we have the problem of multiple comparisons. The chance 
of finding spurious significant differences increases with 
the numbers of comparisons. Furthermore, because we 
only have the results for live births in our cohort, we do 
not know anything about early or late abortions or still-
births for women commencing tapering.
 We do not have measurements for maternal absti-
nence symptoms or well-being during tapering. Neither 
do we know why the women decided to taper their OMT-
medication dose; if it was entirely their own decision or if 
the professionals performing their follow-up played any 
role. Nor do we have measurements of fetal well-being in 
the study. This means that we do not have an assessment 
of how the fetus is responding during tapering. The third 
cohort was interviewed retrospectively, 332 days after de-
livery. This might have led to some recall-bias. Our choice 
of using percentage change in OMT-medication dose 
during pregnancy as the measure for degree of tapering 
also has some limitations. Lastly, the way we have defined 
Table 5.  Outcome for pregnancies and neonates of women in opioid maintenance treatment (OMT), who tapered down or stayed on 
the same dose/increased their OMT-medication dose during pregnancy (n = 123)
Group 1 (n = 21)
Tapered OMT-
medication >50%
Group 2 (n = 30)
Tapered OMT-
medication 11–50% 
Group 3 (n = 72)
Stable or increased dose 
of OMT-medication
Birth outcome
Caesarean section, % 10 23 25
Gestational age at delivery, days, mean ± SD 277±12 271±21 271±19
Methadone-exposed 277±13 265±23 270±19
Buprenorphine-exposed 278±12 280±13 274±18
Preterm birth <37 weeks, % 5 17 21
Neonatal growth
Birth weight, g, mean ± SD 3,245±514 2,982±629 3,037±673
Methadone-exposed 3,252±591* 2,667±604 2,970±648
Buprenorphine-exposed 3,231±350 3,454±272 3,174±718
Birth weight <2,500 g, % 5 17 17
Length, cm, mean ± SD 48.6±2.5 47.5±3.9 47.6±3.8
Methadone-exposed 48.1±2.9 46.1±4.5 47.4±3.1
Buprenorphine-exposed 49.4±1.4 49.3±2.0 48.0±4.8
Head circumference, cm, mean ± SD 34.0±1.4 33.5±2.5 34.2±2.4
Methadone-exposed 34.1±1.4 32.8±2.9 33.8±2.3
Buprenorphine-exposed 33.8±1.5 34.7±1.2 34.9±2.6
Treated for NAS, % 38 63 62
Methadone-exposed 36 61 62
Buprenorphine-exposed 43 67 63
NAS, treatment duration, days, mean ± SD (no. of children) 33.1±17.5 (8) 27.8±14.9 (18) 36.8±22.1 (42)
Methadone-exposed 39.0±15.2 (5) 30.1±18.0 (10) 39.2±23.5 (27)
Buprenorphine-exposed 23.3±19.7 (3) 24.9±10.3 (8) 32.4±19.2 (15)
 * p value <0.05 between Group 1 and Group 2.
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tapering in this study may differ from how the term taper-
ing might be used in other settings.
 The strengths of our study were several. To our knowl-
edge, this was the first study of tapering of opioid agonist 
medication in pregnancy and the resulting neonatal out-
comes for women on methadone or buprenorphine. Sec-
ond, almost all the women in our study were stabilized on 
their OMT-medication from before the pregnancy start-
ed and were well controlled for legal and illegal drugs 
 [29] . Third, the use of legal and illegal drugs is measured 
both by self-report and urine analyses. Finally, the study 
is a national cohort, with both methadone and buprenor-
phine treatment given in the same clinical settings and 
according to the same guidelines.
 Conclusions 
 Some pregnant women maintained on methadone or 
buprenorphine are able to taper the dose of their medica-
tion dose substantially during pregnancy. Tapering more 
than 50% of the initial OMT-medication dose was associ-
ated with significantly higher birth-weights of metha-
done-exposed infants. However, other neonatal out-
comes were not significantly different when the groups 
were compared. There was no apparent harm to mother 
or neonate linked to the tapering.
 Pregnant women in OMT who taper their OMT-med-
ication dose should be monitored closely during their ta-
pering. We need studies that document the maternal 
well-being and the fetal safety of maternal tapering of the 
opioid agonist medication during pregnancy.
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